Who
David P. Meeker
President and CEO
Company insider
Files Form 4 as: President and CEO, Rhythm Pharmaceuticals; Director, Kardigan; Director and 10% owner, Trevi Therapeutics; Director, MyoKardia; Director, Savient Pharmaceuticals; ExecVP,Chief Operating Officer, Genzyme; Director, Penwest Pharmaceuticals Co.
In numbers
- Trades disclosed
- 157
- Buys
- 4
- Sells
- 10
- Bought
- $843K
- Sold
- $18.3M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 3 Jan 2007
- Last trade
- 14 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $303K50,000 at $6.05 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $655K6,439 at $101.75 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.1M30,746 at $102.35 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $900K8,698 at $103.43 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $190K1,817 at $104.55 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $242K2,300 at $105.19 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $303K50,000 at $6.05 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $655K6,439 at $101.75 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.1M30,746 at $102.35 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $900K8,698 at $103.43 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $190K1,817 at $104.55 | filing |
| 14 Sep 2026filed 14 Sep 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $242K2,300 at $105.19 | filing |
| 17 Jun 2026filed 22 Jun 2026 | KARD KardiganBiotechnology | SEC FORM 4 Code A | —20,706 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | KARD KardiganBiotechnology | SEC FORM 4 Code A | —20,706 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,900 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —107,850 at $0.00 | filing |
News
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name David P. Meeker; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.